newsfilter
← Latest News
GlobeNewswire·

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response